ImmuRx is organized around addressing how to change the potential of immunotherapy to treat cancer and chronic infectious disease. By stimulating both the innate and adaptive halves of the immune system, the ImmuRx team has demonstrated significantly greater immune responses and improved therapeutic benefit than most competing adjuvants in a wide variety of disease indications. The firm's very different approach has been found to reduce solid tumor mass, increase survival times in cutaneous and hematapoietic tumor models and protect against both viral and bacterial infections at levels approaching 100% in numerous animal models. The ‘generic’ nature of the ImmuRx platform also suggests the approach may have broader relevance to a wide variety of cancers and infectious diseases. The ImmuRx adjuvant platform synergistically enhances the magnitude and function of cytotoxic T cells, resulting in superior primary and secondary immune responsiveness against cancer and infectious diseases. These advances over competing approaches offer the promise inthe near term of more effective treatment with the potential of perhaps being able to prevent downstream recurrence. Management has assembled a team of leading immunologists, clinical practitioners, intellectual property counsel, and management with the objective of bringing this discovery to the next stage.
